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Abstract
Vaccines have led to significant reductions in morbidity and saved countless lives from many 
infectious diseases and are one of the most important public health successes of the modern era. 
Both vaccines' effectiveness and safety are keys for the success of immunisation programmes. The 
role of post-licensure surveillance has become increasingly recognised by regulatory authorities in 
the overall vaccine development process. Safety, purity, and effectiveness of vaccines are 
carefully assessed before licensure, but some safety and effectiveness aspects need continuing 
monitoring after licensure; Post-marketing activities are a necessary complement to pre-licensure 
activities for monitoring vaccine quality and to inform public health programmes. In the recent 
past, the availability of large databases together with data-mining and cross-linkage techniques 
have significantly improved the potentialities of post-licensure surveillance. The scope of this 
review is to present challenges and opportunities offered by vaccine post-licensure surveillance. 
While pre-licensure activities form the foundation for the development of effective and safe 
vaccines, post-licensure monitoring and assessment, are necessary to assure that vaccines are 
effective and safe when translated in real world settings. Strong partnerships and collaboration at 
an international level between different stakeholders is necessary for finding and optimally 
allocating resources and establishing robust post-licensure processes.
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Introduction
Since the end of the XVIII century, when the first human prophylactic vaccine was 
developed, the number of vaccines available for preventing infectious diseases slowly 
increased until the mid-twentieth century. Antitoxins and bacterial vaccines were mainly 
developed, but a major breakthrough, represented by the ability to grow viruses in cell 
cultures, launched a new era for vaccinology [1]. Since then, the number of diseases that can 
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be prevented by vaccination increased exponentially. Today, 25 diseases are vaccine 
preventable [2]. Poliomyelitis, diphtheria, tetanus, pertussis, hepatitis B, Haemophylus 
influenzae type B, measles, mumps, rubella, pneumococcal infections, rotavirus, disease 
caused by human papillomavirus, and tuberculosis are targeted by childhood vaccination 
programmes worldwide [3]. Moreover, new technologies in vaccine development 
dramatically increased the complexity of modern vaccines: synthetic antigens, innovative 
adjuvants, and conjugated proteins are components of many vaccine products currently in 
use. Such increased complexity brings important challenges during both the authorization 
process and the post-marketing phase in terms of assessment of both effectiveness and 
safety.
Vaccine products reach marketing authorisation after a long development phase that might 
last as long as 12–15 years [4]. Pre-clinical studies (in vitro and in vivo) are necessary to 
select the correct antigenic content so that clinical trials can be designed to be as safe as 
possible. Phase 1 trials provide preliminary information on vaccine safety in humans and on 
the dose to be tested in the following clinical trials. They typically involve a limited number 
of adult volunteers (<100). Candidate vaccines that show promise in pre-clinical evaluation 
and Phase 1 trials undergo Phase 2 trials in order to further evaluate the dose and safety and 
immunogenicity. Phase 2 trials usually involve few hundreds of subjects belonging to the 
final target population of the vaccine (e.g., children for childhood vaccines). Phase 2 studies 
last until the right dose and vaccine schedule is identified (usually a few years). The final 
candidate products progress to Phase 3, when they are studied on a larger scale (from many 
hundreds to many thousands of subjects) to further assess safety and immunogenicity or 
efficacy against the target disease. Generally, concomitant administration with other vaccine 
products is also tested in Phase 3 trials, but it can be done even earlier in the development 
phase [4]. Results from successful vaccine trials are submitted to the regulatory authorities 
for further evaluation and determination of whether market authorisation should be granted 
or not..
Demonstration of effectiveness may be derived from clinical endpoint efficacy studies. In 
some cases, immunogenicity data may be sufficient for a demonstration of effectiveness and 
clinical endpoint efficacy data are not required. Whether immunogenicity data provide 
sufficient evidence of effectiveness depends on the strength of evidence that the immune 
response endpoints predict clinical protection and whether there are sufficiently validated 
assays to measure those endpoints. In such cases, immunogenicity is considered a good 
proxy for vaccine efficacy. This is the case for certain new Hib, Td, or Hepatitis B vaccines 
since for these diseases there are scientifically well-accepted immunological markers that 
predict protection and that can be reliably measured in a validated assay..
After marketing authorisation has been granted, Phase 4 trials and other post-licensure 
surveillance activities can be carried out. Their scope is primarily to assess long-term 
effectiveness and potential safety concerns that were not statistically significant in Phase 3 
trials but merit monitoring in the post licensure setting. Vaccine effectiveness assessed 
during the post-marketing phase is the result of direct vaccine efficacy combined with herd 
immunity. Phase 4 studies are very often an integral part of the authorisation process in 
terms of post-marketing action required by the regulatory agencies to the vaccine 
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manufacturers. Phase 4 studies are complemented by other post-licensure surveillance 
activities that are carried out by different agents (public health institutions, universities, 
research groups) as part of their public health mission.
The role of post-licensure surveillance has become increasingly important during the last 
decades. New methodologies have been developed to enhance efficiency and feasibility of 
post-licensure surveillance [5,6]. More recently, availability of large databases opened a new 
season for post-licensure surveillance by using cross-linkage and data-mining technologies 
[7].
The scope of this review is to present challenges and opportunities offered by vaccine post-
licensure surveillance; and to discuss how, under the current authorisation framework in the 
US and EU, post-licensure surveillance can best complement Phase 3 trials.
The European and U.S. authorisation and public health frameworks for 
vaccine products
In the U.S., regulation of vaccines and other biological products began with the enactment of 
the Biologics Control Act of 1902 following an immunization safety incident in which 
several children died after receiving diphtheria antitoxin that had been contaminated with 
tetanus toxin [10]. The authority to control biologics evolved and was strengthened with the 
passage of additional laws and regulations in subsequent years. One of the major laws was 
enacted as a result of another vaccine safety tragedy -- the “Cutter incident” in 1955, in 
which some batches of polio vaccine had been inadequately inactivated, resulting in polio in 
several vaccine recipients and their contacts [11]. As a result, the U.S. Congress directed the 
creation of a new division at the National Institute of Health (NIH) for the regulation of 
biological products (Division of Biological Standards). Currently, regulatory authority for 
licensure (i.e., market authorisation) of vaccines rests with the Food and Drug 
Administration (FDA) Center for Biologics Evaluation and Research. The process of 
regulation and testing of vaccines has been previously reviewed by Baylor and Midthun 
[10]. Recommendations for routine use of vaccines are issued by the Centers for Disease 
Control and Prevention (CDC), with guidance from its Advisory Committee on 
Immunization Practices [12].
In the U.S., programs to systematically monitor vaccine safety in the post-licensure setting 
began in the late 1970s. Established by CDC in 1978, the Monitoring System for Adverse 
Events Following Immunizations (MSAEFI) collected reports of adverse events in children 
who received publicly funded vaccines [13]. The National Childhood Vaccine Injury Act 
(NCVIA) of 1986 was landmark legislation that established the Vaccine Injury 
Compensation Program and the Vaccine Adverse Event Reporting System (VAERS), which 
replaced MSAEFI in 1990.
In Europe, the European Medicines Agency (EMA) was established in 1995 as a 
decentralised agency of the European Union (EU) for the evaluation of medicines for use in 
member countries. Thanks to a centralised procedure, pharmaceutical companies may 
submit one single marketing-authorisation (MA) application to the EMA. Scientific 
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evaluation of the MA is carried out by scientific committees coordinated by the EMA. The 
Committee for Medicinal Products for Human Use (CHMP), the Paediatric Committee 
(PDCO) and the Pharmacovigilance Risk Assessment Committee (PRAC) are those more 
involved with vaccine products. Committees’ members are nominated by the medicines 
regulatory authorities of the EU Member States, so that geographical representativeness is 
granted and national interests represented. Representatives of patients and healthcare-
professionals may also be part of the committees. Ad hoc working parties are also 
established in order to provide recommendations to the scientific committees for certain 
specific issues. In particular, a Vaccine Working Party has been operational since 2005.
The scientific committee that is in charge of evaluating a MA application appoints a 
rapporteur to lead the assessment. The rapporteur is supported by an assessment team and 
can ask for a peer-reviewed process in order to improve the scientific validity of the process. 
National authorities that provide the staff for the process are remunerated by the EMA. 
Opinions and recommendations presented by the rapporteur are usually adopted in plenary 
sessions of the scientific committees. If consensus cannot be achieved, the final position is 
reached through a vote. On the basis of EMA scientific assessment, the European 
Commission may grant a MA issuing a legally binding EU-wide decision. Vaccines that are 
authorised through this centralised process can be marketed in any country of the EU and 
European Economic Area (EEA - including Iceland, Norway and Liechtenstein).
Specific post-authorization measures (PAM) may be identified by EMA’s committees 
during the scientific assessment phase and are strictly regulated within a legislative 
framework [8]. PAM are not intended to promote premature authorization of medicinal 
products, but are necessary when the manufacturer needs to produce additional data on 
safety and/or efficacy to complement data produced in the pre-authorization phase [9]. Post-
authorization safety studies (PASS), either active studies or meta-analyses, may be carried 
out as part of PAM. In addition, post-authorization efficacy/effectiveness studies may be 
required as part of the risk management plan submitted by the manufacturer as part of the 
application file.
Methodological aspects of Phase 3 trials: strengths and limitations
Phase 3 trials are considered the gold standard to assess vaccine efficacy in the pre-
authorisation phase. Well-designed double/triple blinded, randomised, controlled trials 
(RCT) provide a very robust estimate of vaccine efficacy under standard conditions. 
Nevertheless, some strengths of RCTs can turn into limitations from a public health 
perspective. First of all, in RCTs vaccines are provided under very strict experimental 
conditions in terms of cold chain, schedule, administration technique, etc; standard 
conditions are necessary for experimental purposes and are also needed in the marketing 
authorisation framework, but they may not be strictly adhered to in practice during daily 
vaccination activities. Moreover, in RCTs controlled conditions are pursued as much as 
possible and efficacy estimates in vaccinated individuals may not be influenced by herd 
immunity; whereas, the real life impact of vaccination is affected by herd immunity, which 
is indeed highly desired under a public health perspective. Post-licensure effectiveness 
evaluation is useful both for vaccines that have been evaluated in pre-licensure clinical VE 
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trials as well as those for which pre-licensure effectiveness was based on immunogenicity 
data. In addition, very rare adverse events usually cannot be identified during RCTs, due to 
natural limitations in terms of sample size and study power. [10],[11].
Definitely, RCTs represent the best way to assess vaccine efficacy and safety, but the 
information they can provide needs to be supplemented to support public health decision 
making post-licensure. In particular, RCTs are sometime limited by sample size constraints 
in their ability to evaluate risks for very rare adverse events.
Methodologies for post-licensure surveillance
Effectiveness assessment
Vaccine effectiveness can be defined as the ability of a vaccine to prevent specific outcomes 
in a “real life” situation. Assessing vaccine effectiveness is necessary in order to establish 
the actual benefit of the vaccination in the field. Vaccine effectiveness estimates may 
significantly differ from vaccine efficacy measured during vaccine trials. In fact they may be 
influenced by several factors that are summarised in Table 1.
Several methodologies have been developed for assessing vaccine effectiveness in the field, 
each of them presenting strengths and limitations [5,6,12–19]. Strengths and limitations of 
some of those methodologies that have been extensively used in the recent past are 
summarised in Table 2.
Vaccine effectiveness measured in the field may provide evidence for decision making that 
may not be available at the time of marketing authorisation. Herd immunity effects, degree 
of matching with circulating strains, impact of waning immunity, and changes in microbial 
ecology induced by vaccination are some of the conditions that can be analysed only by 
means of post-licensure surveillance. The ability to address such issues represents an evident 
added value of post-licensure surveillance and makes post-licensure surveillance a valuable 
complement to Phase 3 studies.
Safety assessment
Passive surveillance of adverse events following immunisation (AEFI) and adverse events of 
special interest (AESI) is mandatory after vaccine marketing both in the US and EU. Passive 
spontaneous reporting systems can be valuable for identifying potential new safety concerns 
(i.e., “signals”), but they are subject to several limitations that limit their utility for causality 
assessment (Table 3).
The Vaccine Adverse Event Reporting System, co-managed by CDC and FDA, is the US 
spontaneous reporting system for adverse events after vaccination [20]. VAERS accepts 
reports from healthcare providers, manufacturers, vaccine recipients, and others. Healthcare 
providers are required to report AEs listed in the VAERS Table of Reportable Events 
following Vaccination and are encouraged to report other clinically significant AEs after 
vaccination. Reported AEs are entered into a database and coded using Medical Dictionary 
for Regulatory Activities (MedDRA) terms. Physicians and scientists at FDA and CDC 
regularly review the VAERS reports and conduct periodic safety assessments. FDA has 
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regulatory requirements to conduct scheduled safety assessments of specific vaccines. De-
identified VAERS data also are available for viewing and analysis by the public.
All drugs that are centrally authorised in the EU – vaccines included – are subject to 
mandatory passive surveillance of adverse events at the European level. Individual reports of 
adverse events are managed through the EudraVigilance system [21]. Both reports from 
studies carried out by the manufacturers and spontaneous reports by healthcare professionals 
and regulatory agencies are captured by the system. Data from EudraVigilance are published 
in the European database of suspected adverse drug reaction reports [22]. Individual 
suspected-side-effect reports sorted by age group, sex, type of suspected side effect and 
outcome, can be viewed by any external user. No pharmacovigilance system specific for a 
vaccine product is in place in the EU.
Assessment of passive AEFI reports is carried out by the EMA regularly, according to the 
risk management plan. Routine analysis of EudraVigilance reports - for detecting any 
potential signal - is performed at least monthly; for some medicines, including some 
vaccines, it is done bi-weekly.
While AEFI passive surveillance is quite effective for signal detection purposes, formal 
epidemiologic studies are needed for causality assessment. In addition to traditional 
methodologies, such as cohort and case-control studies, case-only methods have been 
developed in order to improve feasibility of AEFI causality assessment in 
pharmacovigilance settings [23]. Case-only studies provide the great advantage of using 
cases as their own control group, avoiding the need to select external controls. Case-only 
methods are particularly advantageous for assessment of rare AEFI and in situations of 
possible indication bias (e.g., certain vaccines that may be indicated for particular high risk 
groups).
Analytical studies for AEFI causality assessment are facilitated by the availability of large 
databases collecting information on any event of medical interest in large cohorts of 
vaccinees. Large databases and cross-linkage techniques have allowed the recent 
development of new kinds of analyses that would have been impossible a few decades ago. 
The US Vaccine Safety Datalink (VSD) is the oldest such database infrastructure for 
monitoring vaccine safety. Recognizing the need for a flexible, timely and robust system to 
evaluate vaccine safety and supplement information provided by VAERS, CDC established 
VSD in 1990 to conduct post-marketing vaccine safety evaluations in defined populations 
[24]. As a collaboration between CDC and several large health care organizations, VSD 
conducts population-based monitoring and research on important immunization safety 
questions. VSD has the capacity to address a wide array of safety issues, including 
monitoring new vaccines in children and adults and conducting timely evaluations of new 
vaccine safety signals. The aggregate population across all sites is sufficiently large so that 
risk can be assessed for rare adverse events. Data from approximately 9.3 million 
individuals are available annually, including 2.1 million children and 7.2 million adults. 
VSD has cumulative information on more than 21 million individuals who have collectively 
received over 134 million vaccine doses. Building on the VSD model, FDA has recently 
established the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) system that 
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links data from several large health insurance companies. PRISM is integrated within the 
Mini-Sentinel project [25] and enhances the national capacity for vaccine safety monitoring 
by assembling vaccination and outcomes data on an additional large population [26].
In Europe, the VAESCO consortium has been initiated and sponsored by the ECDC with the 
aim of improving the sensitivity and timeliness of vaccine safety monitoring systems [27]. 
Large database linkage has been successfully used by VAESCO partners on several 
occasions [28–30].
Illustrative case studies of the added value of post-licensure surveillance
Effectiveness of Acellular Pertussis vaccines
Acellular pertussis vaccine trials have represented one of the biggest public investments in 
the history of vaccine development. By the mid-1980’s the US NIH, worried about the 
increasing public concern about the safety of cellular pertussis vaccines, boosted research on 
acellular vaccines [31]. Large acellular pertussis trials were conducted in the 1990’s, 
assessing safety and efficacy of DTaP vaccines in infants [32,33]. Efficacy estimates from 
the Phase 3 trials were very consistent, showing protective efficacy of more than 80% in 
children vaccinated with acellular vaccines; on the other hand efficacy of cellular vaccines 
was very variable. Moreover, acellular vaccines showed much higher tolerability [34]. As a 
consequence, beginning in the late 1990’s acellular vaccines rapidly replaced cellular 
vaccines both in the US and in Europe and vaccine coverage against pertussis increased 
[35]. Notwithstanding high coverage rates, resurgence of pertussis has been recently 
reported both in the US and in Europe; in particular, high incidence rates have been reported 
in adolescents and young adults as well as small infants [36–39]. The increase has been 
attributed to different factors, including earlier than expected waning of immunity; a shift of 
pertussis circulation in those age groups not covered by vaccination and subsequent 
transmission to unvaccinated infants; and possible vaccine failure due to emergence of 
Bordetella pertussis mutant strains [38,40–44]. Whatever the reason, the resurgence of 
pertussis indicates a need for a revision of current pertussis vaccination strategies guided by 
a thorough assessment of pertussis epidemiology and vaccine effectiveness. The unexpected 
resurgence of pertussis in some countries, however, is not in contradiction with the reported 
high vaccine efficacy after Phase 3 trials. Even in the presence of high individual efficacy 
after primary vaccination [32,33] and reasonably good sustained efficacy after 5 years 
[45,46], infant vaccination alone seems to be far from sufficient to stop the overall 
circulation of Bordetella pertussis. Alternative strategies including adolescent/adult 
vaccination [39,47–49] and vaccination in pregnancy [50]have been implemented in many 
countries. In order to inform new vaccination strategies and to better understand the reasons 
behind pertussis resurgence, both disease and vaccine post-licensure surveillance are 
paramount [51–54].
Effectiveness of Influenza vaccines
Immunogenicity and safety of influenza vaccines is systematically assessed by means of 
Phase 3 trials for MA purposes. Unfortunately, due to the frequent drifts and shifts of 
influenza viruses, pre-licensure trials, carried out for regulatory purposes, do not always 
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anticipate the impact of influenza vaccination public health campaigns. Several systematic 
reviews of the literature reported limited impact of influenza vaccination in children below 2 
years, healthy adults, and the elderly [55–57]. Mismatch between vaccine and circulating 
strains is one of the most important factors for low influenza vaccine effectiveness. Thus, 
influenza vaccine effectiveness should be routinely measured in order to better understand 
the role and impact of vaccination strategies under different epidemiological circumstances. 
For this purpose, the US Flu VE Network [58] was established and the I-MOVE network 
was established in Europe in 2007. Repeated estimates of influenza vaccine effectiveness 
have been provided by I-MOVE throughout different influenza seasons [18]. Not 
surprisingly, one of the highest vaccine effectiveness estimates (71.9%; 95% confidence 
interval 45.6–85.5) has been reported during the 2009–10 season, when the pandemic 
A(H1N1)pdm09 virus was the almost exclusive circulating strain and was well matched to 
the vaccine strain [19]. Unfortunately, effectiveness estimates, in the best case scenario, are 
available a few months after the influenza season is over and may not be applicable to the 
next season (i.e., because of strain changes). Nevertheless, continuing evaluation of 
influenza vaccine effectiveness can provide important information for public health 
decisions in terms of vaccine effectiveness in different age groups, the added value of 
adjuvants, and the effectiveness of different vaccine types. Increasing knowledge on the 
impact of influenza vaccination is of high value for public health.
European Experience: Pandemrix and Narcolepsy
In August 2010 public health authorities in Finland and Sweden reported an increase of 
cases of narcolepsy in children and adolescents, suggesting a potential association with 
Pandemrix vaccination. Eight influenza A(H1N1)pdm09 vaccines were licensed for use in 
Europe during the 2009 pandemic, but Pandemrix was the most frequently used vaccine in 
Europe: based on EMA estimates, more than 30.5 million people were vaccinated with 
Pandemrix in the EU/EEA [59]. In Finland and Sweden, Pandemrix was the only vaccine 
used for the pandemic vaccination campaign.
Narcolepsy is a rare neurological disorder characterized by inability to regulate sleep-wake 
cycles normally. The primary symptom is excessive daytime sleepiness. Narcolepsy 
predominantly affects adolescents and young adults, and very rarely children under 16 years 
of age. Sudden onset of short episodes of muscle tone loss, known as cataplexy, may occur 
as part of the neurological disorder [60]. Abnormal immunological response to different 
antigens, combined with specific genetic patterns, is suspected to be the trigger for 
narcolepsy [61,62].
The VAESCO consortium, supported by the ECDC, coordinated a multinational 
investigation to assess the causality relationship between narcolepsy and Pandemrix [27]. 
Eight European countries (Denmark, Finland, Italy, the Netherlands, Norway, Sweden, and 
the United Kingdom) participated in a case-control study using a common protocol, 
common case report forms, and a common Brighton Collaboration case definition. This 
study confirmed a strong statistical association between Pandemrix and onset of narcolepsy 
in children and adolescents in Finland and Sweden [59], in line with independent analyses 
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carried out by national authorities [63–66]. Further studies, carried out at national levels in 
Norway, Ireland, and England identified an association in those countries as well [67–69].
In conclusion, after the signal raised in Finland and Sweden, a strong association between 
narcolepsy and influenza A(H1N1)pdm09 vaccination has been established in some 
European countries, but not in others and nowhere else outside Europe. It is still unknown if 
the vaccine was the cause of the neurological disorder or if it was just the trigger speeding 
up disease onset in individuals who would otherwise have developed narcolepsy later. This 
will become clear in the coming years, as results become available from studies in other 
countries as well as research on the pathogenic mechanisms of narcolepsy that has been 
stimulated by this event. In this episode, post-licensure surveillance was demonstrated to be 
effective in detecting a signal of a serious AEFI at national levels, and international 
collaboration has been extremely fruitful for the following signal assessment.
Rotashield and intussusception
The first vaccine designed to prevent rotavirus infection (Rotashield® – Wyeth Lederle 
Vaccines, Philadelphia, PA) was voluntarily withdrawn from the US market by the 
manufacturer in 1999 due to an increased risk of intussusception among infants receiving the 
vaccine [70]. The identification and investigation of this safety problem provides an 
excellent illustration of a post-licensure vaccine safety monitoring system that worked well 
to inform vaccination policy. In the pre-licensure trials for Rotashield®, a small increase in 
the number of cases of intussusception had been observed, but the results were not 
statistically significant. As a result, FDA and CDC were on the alert to closely monitor for 
intussusception after Rotashield® was licensed in the US in August 1998 and subsequently 
recommended for universal infant immunization in March 1999. By May 1999, nine cases of 
intussusception had been reported to VAERS following Rotashield®, whereas VAERS had 
received only 3 reports of intussusception following all vaccines administered from 1990 to 
1998. In response to the VAERS signal, along with other data, CDC initiated two 
confirmatory studies and suspended the recommendation for Rotashield® vaccination 
pending the results of those studies. The first study was initiated in VSD and expanded to 
include 10 large medical care organizations. Using the computerized databases of the 
participating medical care organizations, with chart confirmation of intussusception cases, a 
cohort study was conducted that found a large increased risk of intussusception associated 
with Rotashield® vaccination; the highest relative risk of 31 occurred during days 3–7 after 
the first dose [71]. The second study was a large case-control study conducted in 19 states, 
which also found a strong association with Rotashield® with a peak relative risk of 36 at 3–7 
days after the first dose [72]. As a result of these findings, in October 1999 the manufacturer 
stopped marketing the vaccine and ACIP withdrew its recommendation for the vaccine.
Two new rotavirus vaccines were subsequently licensed following large pre-licensure trials 
that did not find an increased risk of intussusception. In post-licensure monitoring, however, 
a small increased risk of intussusception was detected for both vaccines [73,74]. Post 
licensure data have also documented large benefits of rotavirus vaccination in terms of 
reductions in hospitalizations, ER visits, and in some cases, deaths from diarrhea [75]. Thus, 
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policy makers have continued to recommend the current rotavirus vaccines for childhood 
immunization programs.
Conclusion
Pre-licensure activities form the foundation for the development and licensure of effective 
and safe vaccines. Pre-licensure activities, including the pivotal Phase 3 trials, cannot be 
replaced by post-licensure monitoring systems. Post-licensure monitoring and assessment, 
however, are necessary adjuncts to pre-licensure activities to assure that vaccines are 
effective when translated from the somewhat idealized clinical trial setting to wider 
population groups in real world settings. After licensure, robust vaccine safety monitoring 
systems are essential for providing assurance of the safety of vaccines and rapidly 
identifying and responding to potential safety problems, particularly rare health conditions 
that pre-licensure trials may not have had the power to detect. Currently, spontaneous 
reporting systems serve as the principal mechanisms for the early identification of potential 
vaccine safety problems. Spontaneous reporting systems, however, have many limitations, 
with under-reporting being foremost among them. Possible technological advances could be 
employed to improve reporting completeness and accuracy, including application of Web-
based and text messaging technologies to make reporting easier and more accurate.
An optimal vaccine safety monitoring system must include a capability to rapidly conduct 
formal epidemiologic evaluations of potential safety problems identified from spontaneous 
reporting systems or other sources. This function can be most readily served by the 
establishment of standing infrastructures of large linked healthcare databases, such as the 
VSD project. The diffusion of electronic health records and the capability to link records 
across health data systems and immunization registries may allow the expansion of 
populations that could be included in post-licensure epidemiologic evaluations of vaccine 
safety.
New technologies and innovative epidemiological methods also can be beneficial to improve 
post-licensure assessment of vaccine effectiveness and impact on population health. Data on 
disease epidemiology, disease burden, vaccine coverage, vaccination status of disease cases 
are necessary for effectiveness and impact assessment. Those data are usually available in 
different databases hosted by different public health agencies. Strong partnerships between 
regulatory and public health authorities as well as academia and vaccine manufacturers 
would be necessary to facilitate such activities. Moreover, due to the large sample size 
required for those kinds of studies, international collaboration and coordination is 
paramount. The legal regulatory framework also plays a crucial role: enhancing the 
importance of post-licensure surveillance in the regulatory process could facilitate allocation 
of adequate resources and foster collaboration among all involved stakeholders.
Vaccines are one of the most important public health successes of the modern era. They 
have led to significant reductions in morbidity and saved countless lives from many 
infectious diseases. The success of vaccination programs depends on both vaccines' 
effectiveness and their safety. Robust systems to monitor and evaluate vaccines after they 
are licensed and are widely administered are critical to maintaining the public’s confidence 
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in and acceptance of vaccines, as well as to assure that the vaccines are providing the level 
of protection and safety anticipated when they were licensed.
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Table 1
Factors affecting vaccine effectiveness
● Host Factors
  ○ Age
  ○ Presence of conditions/co-morbidities that may either affect immune response or influence individual disease susceptibility
  ○ Previous exposure to antigen
  ○ Interference due to co-administered vaccines or other drugs
● Logistic issues
  ○ Schedule compliance
  ○ Cold chain
  ○ Administration issues
● Epidemiological factors
  ○ Force of infection
  ○ Herd immunity
  ○ Mismatch with circulating strains
  ○ Emergence of new viral/bacterial variants
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Table 2
Some strengths and limitations of different methodologies for assessing vaccine effectiveness.
Method Strengths Limitations
Screening method • Use of routinely collected data
• Rapid and not expensive
• Suboptimal accuracy and completeness of 
routinely collected data
• Does not provide precise estimates of 
vaccine effectiveness
Outbreak investigation • Good estimates provided under certain 
circumstances (closed communities, low 
disease incidence in the past, high attack 
rates)
• During community-wide outbreaks 
cluster sampling can be performed
• Control programmes during the outbreak 
can severely interfere
• Exposure can be different among 
vaccinees and non-vaccinees
Coverage survey method • Similar approach as in outbreak 
investigation, but does not require any 
actual outbreak
• Similar resources required as for 
coverage survey
• Exposure can be different among 
vaccinees and non-vaccinees
• Can be used only in endemic areas
• Recall bias may affect the accuracy of 
case ascertainment
Secondary attack rates in 
households or clusters
• Bias due to different exposure among 
vaccinees and non-vaccinees is reduced
• Small number of children available
• Families should be followed-up for a time 
longer than the incubation period
• Method of secondary attack rates in 
clusters is less rigorous
Case-control studies • Good use of resources
• Useful when access to data from clinics 
is easier than access to vaccination 
records
• Correct selection of controls is crucial to 
limit bias
• Potential confounders must be seriously 
addressed
Time-series analysis • Use of routinely collected data
• May evaluate both direct and indirect 
(herd immunity) vaccination effects
• Limits of any ecological approach
Indirect cohort design • More efficient than cohort studies
• Suitable for rare diseases (pneumococcal 
infections)
• May under-estimate vaccine effectiveness 
because cross protection against non-
vaccine types cannot be controlled
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Table 3
Some strengths and limitations of spontaneous reporting systems.
Strengths Limitations
• Rapid signal detection (hypothesis generation) • Reporting bias (e.g., underreporting, stimulated reporting) routinely 
collected data
• Cover large population • Inconsistent data quality and completeness
• Can detect rare adverse events • Lack of unvaccinated comparison group
• Relatively inexpensive • Not designed to assess if a vaccine caused an adverse event
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